CLINICAL_TRIALS
trial_result
· 2018-04-18
Clinical Trial Update: A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer [Phase 2]
Summary
Phase 2 clinical trial update for cixutumumab (IMC-A12) in islet cell cancer, with completed status and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2018-04-18